MASHINIi

Foghorn Therapeutics Inc..

FHTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Foghorn Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing a novel class of medicines targeting genetically determined dependencies in cancer. The company's proprietary Gene Traffic Control platform enables the identification and validation of chromatin regulato...Show More

Ethical Profile

Mixed.

Foghorn Therapeutics Inc. focuses on developing novel cancer therapies, including for prostate, bladder, and lung cancers, using a unique chromatin regulation approach, and collaborates with Eli Lilly. Internally, employee sentiment appears strong, with Glassdoor reviews showing 4.4/5 for culture, 4.7/5 for diversity, and 100% CEO approval. The CEO's compensation was $1.56 million in 2024, a 38% decrease from 2023. However, some employees reportedly note a lack of 401k match. The company engages in animal testing as part of its drug development, though specific details on testing volume or reduction policies are not publicly available. Information regarding Foghorn's environmental impact, ethical sourcing, or broader community engagement is currently insufficient for a comprehensive assessment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect30
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-30
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Foghorn Therapeutics Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

The provided article details Foghorn Therapeutics Inc. as a biopharmaceutical company focused on developing medicines for cancer, outlining its financial metrics, drug pipeline, and strategic partnerships.

1
The article explicitly states that no data relevant to 'Fair Money & Economic Opportunity' is present.
2
As the company's core business is not in financial services, and no evidence is provided regarding lending, insurance, or other financial products or services, all KPIs related to this value are omitted due to a lack of specific, concrete data points in the article.

Fair Pay & Worker Respect

30

Based on 13 employee reviews, the company has an overall Glassdoor rating of 4.69 out of 5, with high ratings for diversity, equity & inclusion (4.7/5), work/life balance (4.6/5), and culture & values (4.4/5).

1
The CEO approval rating is 100%.
2
There are no mentioned regulatory actions, violations, fines, or compliance issues related to labor or human rights.
3

Fair Trade & Ethical Sourcing

0

No information regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in contracts, spend on high-risk materials, or supplier diversity was found in the provided articles for Foghorn Therapeutics Inc.

1

Honest & Fair Business

-30

Foghorn Therapeutics Inc. has a Clawback Policy addressing financial restatements due to material noncompliance.

1
The company has an anti-corruption policy that prohibits bribery and corruption, requires pre-approval for providing anything of value to foreign officials, and includes third-party due diligence for partners, but lacks customization for high-risk areas.
2
The Board of Directors has determined that all but one director are independent, meaning approximately 88% of the board is conflict-free.
3
The Audit Committee pre-approved 100% of services performed by the independent registered public accounting firm, Deloitte & Touche LLP, since the pre-approval policy was adopted.
4
The company has an independent third-party employee hotline through Navex Global for reporting, which allows for anonymous submissions and prohibits retaliation.
5
However, there is no evidence of independent investigation processes or communication to all staff. Managers are expected to respond to inquiries or refer questions to appropriate personnel within one week.
6
Approximately 45% of ethical claims are independently verified, with verification becoming more systematic.

Kind to Animals

0

The company engages in animal testing, as evidenced by its use of mouse tumor models in research

1
and a general statement confirming animal testing.
2
However, the provided articles do not offer any quantitative data regarding the volume of animals used, the specifics of its animal testing policy, or the extent to which non-animal testing methods are employed. No information is available on cruelty-free certifications, humane certifications for operations, ethical sourcing, or any other animal welfare-related metrics.

No War, No Weapons

0

No evidence available to assess Foghorn Therapeutics Inc. on No War, No Weapons.

Planet-Friendly Business

-20

The company has no recorded environmental compliance violations, fines, or compliance issues, indicating an exemplary compliance history.

1

Respect for Cultures & Communities

0

No specific, concrete data points were found across the provided articles to assess Foghorn Therapeutics Inc. against any of the KPIs for 'Respect for Cultures & Communities'. The articles primarily focus on SEC filings, company leadership, research publications, conference participation, and internal HR policies related to non-discrimination and harassment. Information regarding community engagement, cultural impact assessments, local employment, or specific grievance mechanisms for external community concerns is not present.

Safe & Smart Tech

0

Foghorn Therapeutics reported no unauthorized data use incidents in 2021.

1
The company has implemented Egnyte's Secure & Govern solution to gain visibility into sensitive content, created eight custom policies for data classification, and leverages permission controls and robust reporting.
2
The company's privacy policy outlines user rights to access, rectify, erase, restrict, object, and port their personal information in certain jurisdictions, which is an industry-standard approach.
3
Data is retained only as long as necessary for processing purposes, and anonymized or securely destroyed when no longer needed.
4
The company aims to prevent unlawful or criminal activity and security issues, and its Audit Committee oversees the integrity of information technology systems, processes, and data.
5
A board member holds a NACD Cybersecurity Expert Certification from 2024.
6
The company files Form 10-Q with the SEC, indicating compliance with SEC regulations for quarterly reporting, and its privacy policy mentions compliance with CCPA and other jurisdictions' data subject rights.
7
However, the company is an "emerging growth company" and intends to rely on exemptions from certain disclosure requirements.
8
The company uses technical, administrative, and procedural measures to safeguard personal information and verifies identity when processing requests related to personal information.
9
Foghorn Therapeutics built a secure clinical data repository using Egnyte and created custom policies for sensitive content, which suggests privacy considerations in development.
10

Zero Waste & Sustainable Products

0

No specific, concrete data points were found in the provided articles for Foghorn Therapeutics Inc. (FHTX.US) regarding any of the KPIs related to Zero Waste & Sustainable Products.

1
The articles either discuss other companies' sustainability efforts or explicitly state that data for FHTX.US is missing for these metrics.

Own Foghorn Therapeutics Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.